Document Detail


Essential medicine policy in China: pros and cons.
MedLine Citation:
PMID:  23215958     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Objective: To analyze the achievements, issues and policy recommendations for implementing essential medicine system in China after a 3-year effort. Methods: Policy documents analysis and Literature reviews are conducted. Results: From 2009-2011, a series of national essential medicine (EM) policies has been established which contain EM list, organizing production, quality assurance, pricing, tendering and procurement, distribution, rational use, monitoring and evaluation, etc. About 98.8% government-run primary healthcare institutions and 41.5% village health posts are conducting zero-mark-up policy while buying EMs. The average cost per visit, per admission, and per description in outpatient and inpatient departments has declined. The Issues with the national EM list cannot meet the requirements of clinical practice at the local level, all provinces have to increase additional 64-455 EMs in their local supplementary list; the limitation of EML in primary healthcare institutions causes patients to transfer directly to secondary or tertiary hospitals to search appropriate treatment; there is no defined regulation or legislation regarding the responsibility and accountability of government to compensate for the financial loss after implementing a zero mark-up policy in primary healthcare institutions. In the future, some innovative reform should be taken into account, such as revising EML, quality assurance, control margins within the distribution system, differential pricing and internal reference-based pricing, waive taxes and import duties of EMs, and separation between prescribing and dispensing in public hospital reform. Conclusions: Establishing a national essential medicine system is a difficult task to accomplish. The role of the zero-mark-up policy of EMs is to cut off the economic profit chain among different stakeholders. Using pharmaceutical profit to subsidize hospital revenue will be gradually eliminated in China.
Authors:
Shanlian Hu
Related Documents :
2084218 - Statistics as a tool in practice management.
24783328 - Design-led choice is a growing feature.
10272458 - Hmo participation. must you surrender control?
10172718 - Error budgets for quality management--practical tools for planning and assuring the ana...
9343918 - Management of the patient with disruptive vocalization.
9684418 - Tackling warts on the hands and feet.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-7
Journal Detail:
Title:  Journal of medical economics     Volume:  -     ISSN:  1941-837X     ISO Abbreviation:  J Med Econ     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Erythrocytosis in a Child due to Hb Andrew-Minneapolis [?144(HC1)Lys?Asn (AAG>AAT or AAC)] Associate...
Next Document:  The experience of fatigue in people with inflammatory bowel disease: an exploratory study.